Zhuo et al. [13] reported that SRPK2 protein expression was significantly associated with more advanced pathological stage in their own clinical TMA (tissue microarray) cohort and the TCGA (The Cancer Genome Atlas) dataset in prostate cancer. Here, SRPK2 is linked to prostate carcinoma.